Table 1

Characteristics of the study sample, by cohort

CharacteristicSTR (n=1797)2+PPD (n=5584)p Value
Age (mean (SD))41.6(10.56)42.32(11.37)0.0137
Gender (N, %)
 Male94552.59306354.850.1123
 Female85247.41252145.150.1439
Race (N, %)
 White38721.54122121.870.8893
 Black118766.05365865.510.6877
 Hispanic181.00821.470.7844
 Other20411.3562111.120.7846
 Unknown10.0620.040.8766
Basis of medicaid eligibility (N, %)
 Aged10.0680.140.5634
 Disabled108960.60407172.90<0.0001
 Income58332.44115920.76<0.0001
 Other583.232023.610.8710
 Unknown653.621412.530.0487
Medicare eligibility (N, %)
 Not dually eligible179199.67555899.530.9987
 Dually eligible50.28240.430.6523
 Unknown10.0520.040.9014
 Charlson comorbidity index score, mean (SD)0.67(1.38)0.65(1.36)0.5919
Concomitant mental health and substance abuse comorbidities (N, %)
 Mental disorders38221.26134024.000.0456
 Drug or alcohol abuse33818.8185615.330.0323
Treatment naïve at index85347.47136624.46<0.0001
Regimen length, mean (SD)348.17(259.32)433.46(351.50)<0.0001
Index medications (N, %)
 NRTI1797100.005584100.00
 NNRTI1797100.00150026.86<0.0001
 PI406472.78
 Kaletra at index163340.18
 Boosted PI at index166440.94
 Non-boosted PI at index76718.87
 PE171230.66
 Other871.56
  • 2+PPD, two or more pills per day; NNRTI, non-nucleoside/nucleotide reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; PE, pharmacokinetic enhancer; PI, protease inhibitor; STR, once-daily single-tablet regimen.